Jan 17, 2012 by Brian Orelli, PhDYou Can Forget About Seeing This Drug WorkMedivation and Pfizer's Dimebon fails again.
Jan 15, 2012 by Brian Orelli, PhDWarning: Don't Sell on This NewsSeattle Genetics' warning label isn't as bad as it sounds.
Jan 15, 2012 by Brian Orelli, PhD3 Lessons From the J.P. Morgan Health-Care ConfabAfter 30 years, the conference still offers useful takeaways.
Jan 13, 2012 by Brian Orelli, PhDThe Best Big Pharma DividendFinding out which companies will reward investors the most.
Jan 11, 2012 by Brian Orelli, PhDA Year's Worth of Sales in 1 MonthRegeneron's Eylea hits the gates running.
Jan 6, 2012 by Brian Orelli, PhDDon't Read Too Much Into This PartnershipSometimes a deal is just a deal, not a sign of M&A to come.
Jan 5, 2012 by Brian Orelli, PhDAre These Biotech Drug Launches Back on Track?Good signs, but let's not call it a trend yet.
Jan 4, 2012 by Brian Orelli, PhDThis Biotech's Obese To-Do List Is DoneArena resubmits lorcaserin for FDA approval.
Jan 4, 2012 by Brian Orelli, PhDMark Your Calendars, Biotech InvestorsCell Therapeutics' advisory panel meet ought to be entertaining.
Jan 3, 2012 by Brian Orelli, PhDHigh Expectations Trump Solid ResultsAVEO slumps despite solid results for tivozanib.
Dec 31, 2011 by Brian Orelli, PhD3 Stock-Moving Binary Events to Watch in 2012A look at what's coming up in biotech.
Dec 31, 2011 by Brian Orelli, PhD3 More Stock-Moving Binary Events to Watch in 2012A quick look at some drugs waiting for review.
Dec 30, 2011 by Brian Orelli, PhDWorking Through the Obese To-Do List in 2011Arena ends the year on an upswing.
Dec 30, 2011 by Brian Orelli, PhDA Bad Year for the 6,300% MiracleHuman Genome Sciences falls from grace.
Dec 29, 2011 by Brian Orelli, PhDWhat to Look For From Keryx and Aeterna Zentaris in 2012The future is uncertain for these pharmaceutical companies.
